Improved imaging agent pinpoints hostile cancer

by Chris Thomas
The study assessed whether the PET imaging test could ascertain whether there was residual tumour or inflammation present midway through chemotherapy treatment. Credit: Jenny Mealing

Positron emission tomography (PET) could prove to be a better imaging procedure than magnetic resonance imaging (MRI) in the detection of glioblastoma, the most aggressive type of primary brain tumour.

Funded by a Cancer Council WA grant of more than $143,000, researchers at the University of WA's School of Medicine and Pharmacology are testing a new PET that collects in high levels in glioma cells but low levels in normal brain tissue.

The imaging agent O-(2-[18F]-fluoroethyl)-L-tyrosine, known as FET, has already shown promise in clinical studies with treatment planning and monitoring treatment response and outcome in a small number of glioblastoma patients.

UWA Associate Professor Roslyn Francis says the aim is to validate the imaging test in more patients and assess whether FET-PET can be used for routine management of patients with glioblastoma.

"FET is an amino acid PET imaging agent," she says.

"Clinical studies have shown amino acid transport is increased in malignant transformation of a variety of tumours.

"Agents such as FET demonstrate activity in both low-grade and high-grade glioblastoma and are independent of disruption to the blood-brain barrier.

"This imaging modality is complementary to MRI and can increase sensitivity of imaging because the uptake can be seen in sites of tumours that are non-enhancing on MRI."

Previously, the research team conducted a clinical study with 30 patients using the related agent C11-methionine—another amino acid PET but with a shorter half-life.

The study assessed whether the PET imaging test could ascertain whether there was residual tumour or inflammation present midway through chemotherapy treatment.

"Our current study aims to validate FET-PET imaging as a clinical tool in glioblastoma by establishing reproducible imaging protocols, acquisition parameters, quantitative guidelines and determining inter and intra-observer variability," A/Prof Francis says.

Response assessed to chemoradiotherapy

"Data will also be collected on the utility of FET-PET imaging for assessing response to treatment with chemoradiotherapy in a cohort of patients with .

"The aim is to use the results of this initial single site study to form the basis of a multicentre imaging cohort study across several sites in Australia."

A sub-study will also assess how FET-PET imaging may impact on a planned radiotherapy treatment volume compared to using MRI alone.

It will utilise baseline FET-PET collected as part of the main research project.

"It's an image analysis study where we will hopefully gain information to ascertain whether incorporating areas of FET uptake into a radiotherapy planning field may influence sites of subsequent disease progression or relapse," A/Prof Francis says.

add to favorites email to friend print save as pdf

Related Stories

Perfecting the combined MR/PET

Jun 03, 2014

PET (Positron Emission Tomography) is an imaging technique that provides insight into the metabolic and functional alterations related to pathologic process. CT (Computerized X-Ray Tomography) and MRI (Magnetic ...

Recommended for you

Marker polyps do not cause cancer

4 hours ago

Although serrated polyps usually are associated with colorectal cancer, it turns out that such polyps are themselves not dangerous, according to a Norwegian study released this week in BMJ Gut.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.